Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | MAOA | P21397 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | S100A4 | P26447 | 2/20 | 0.57 |
| ▸ | APAF1 | O14727 | 2/20 | 0.57 |
| ▸ | TDP2 | O95551 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | CES2 | O00748 | 1/20 | 0.57 |
| ▸ | TERT | O14746 | 1/20 | 0.57 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.57 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.57 |
| ▸ | BCHE | P06276 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | PTPRC | P08575 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL19583256 | 0.95 | MEN1 (0.53) | MEN1KMT2AMAPK1NPC1MAOA | |
| Hydrochloric Acid SCHEMBL2296340 | 0.95 | MEN1 (0.53) | MEN1KMT2AMAPK1NPC1MAOA | |
| Hydrochloric Acid SCHEMBL28596065 | 0.95 | MEN1 (0.53) | MEN1KMT2AMAPK1NPC1MAOA | |
| SCHEMBL29067593 | 0.94 | MEN1 (0.61) | MEN1KMT2AMAPK1NPC1MAOA | |
| SCHEMBL11875421 | 0.94 | MEN1 (0.61) | MEN1KMT2AMAPK1NPC1MAOA | |
| SCHEMBL29711875 | 0.94 | MEN1 (0.61) | MEN1KMT2AMAPK1NPC1MAOA | |
| SCHEMBL28904690 | 0.94 | MEN1 (0.61) | MEN1KMT2AMAPK1NPC1MAOA | |
| SCHEMBL29437946 | 0.94 | MEN1 (0.61) | MEN1KMT2AMAPK1NPC1MAOA | |
| SCHEMBL58152 | 0.94 | MEN1 (0.61) | MEN1KMT2AMAPK1NPC1MAOA | |
| SCHEMBL49870 | 0.94 | MEN1 (0.61) | MEN1KMT2AMAPK1NPC1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 608 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814623-B2 | Methods of treating a wound using epigenetic regulation | UNIVERSITY OF MASSACHUSETTS (US) | 2023-11-14 | — | — | US | claimed |
| CN-116368384-A | Compounds, targets and pathways for macrophage modulation | 麻省理工学院 | 2023-06-30 | — | — | CN | claimed |
| US-11674140-B2 | Compositions and methods for treating facioscapulohumeral dystrophy | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-06-13 | — | — | US | claimed |
| CN-116035020-A | Reagent for overcoming self-incompatibility of white birch, and use and application thereof | 东北林业大学 | 2023-05-02 | — | — | CN | claimed |
| US-20220259302-A1 | METHODS AND COMPOSITIONS FOR THE IMPROVEMENT OF LYSOSOMAL FUNCTION AND TREATMENT OF NEURODEGENERATIVE DISEASE | UNIV VANDERBILT (US) | 2022-08-18 | — | — | US | claimed |
| US-20210187072-A1 | METHODS AND COMPOSITIONS FOR REDUCING RISK OF RELAPSE AND PROLONGING SURVIVAL IN ACUTE MYELOID LEUKEMIA | MARTNER ANNA (SE) | 2021-06-24 | — | — | US | claimed |
| US-20210163931-A1 | COMPOSITIONS AND METHODS FOR TREATING FACIOSCAPULOHUMERAL DYSTROPHY | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2021-06-03 | — | — | US | claimed |
| US-20200354445-A1 | METHODS AND COMPOSITIONS FOR THE IMPROVEMENT OF LYSOSOMAL FUNCTION AND TREATMENT OF NEURODEGENERATIVE DISEASE | VANDERBILT UNIVERSITY | 2020-11-12 | — | — | US | claimed |
| EP-3710114-A1 | METHODS AND COMPOSITIONS FOR THE IMPROVEMENT OF LYSOSOMAL FUNCTION AND TREATMENT OF NEURODEGENERATIVE DISEASE | Vanderbilt University (US) | 2020-09-23 | — | — | EP | claimed |
| CN-111565715-A | Mitoflavoscin: elimination of Cancer Stem Cells (CSCS) by inhibition of mitochondrial respiration with enzymes containing targeted flavins | 卢内拉生物技术有限公司 | 2020-08-21 | — | — | CN | claimed |
| WO-2002004657-A2 | SCREENING METHOD | EIRX THERAPEUTICS LIMITED (IE) | 2002-01-17 | — | — | WO | claimed |
| WO-2000027423-A2 | METHODS AND COMPOSITIONS FOR TREATING COMMON COLD SYMPTOMS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2000-05-18 | — | — | WO | claimed |
| EP-0784471-A4 | MULTI-FACETED METHOD TO REPRESS REPRODUCTION OF LATENT VIRUSES IN HUMANS AND ANIMALS | DYKE KNOX VAN (US) | 1997-11-19 | — | — | EP | claimed |
| EP-0784471-A2 | MULTI-FACETED METHOD TO REPRESS REPRODUCTION OF LATENT VIRUSES IN HUMANS AND ANIMALS | Van Dyke, Knox (US) | 1997-07-23 | — | — | EP | claimed |
| WO-1996031217-A9 | INHIBITING RETROVIRAL REPLICATION | — | 1996-11-28 | — | — | WO | claimed |
| WO-1996031217-A1 | INHIBITING RETROVIRAL REPLICATION | DUKE UNIVERSITY (US) | 1996-10-10 | — | — | WO | claimed |
| WO-1996010402-A1 | MULTI-FACETED METHOD TO REPRESS REPRODUCTION OF LATENT VIRUSES IN HUMANS AND ANIMALS | DYKE KNOX VAN (US) | 1996-04-11 | — | — | WO | claimed |
| WO-1996002241-A9 | USE OF NITROGEN OXIDE SPECIES AND ADDUCTS TO INHIBIT SKELETAL MUSCLE CONTRACTION | — | 1996-02-29 | — | — | WO | claimed |
| WO-1996002268-A1 | INHIBITION OF VIRUS BY NITRIC OXIDE | BRIGHAM AND WOMEN'S HOSPITAL (US) | 1996-02-01 | — | — | WO | claimed |
| WO-1996002241-A1 | USE OF NITROGEN OXIDE SPECIES AND ADDUCTS TO INHIBIT SKELETAL MUSCLE CONTRACTION | DUKE UNIVERSITY (US) | 1996-02-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163931-A1 | COMPOSITIONS AND METHODS FOR TREATING FACIOSCAPULOHUMERAL DYSTROPHY | MYOF, MTPN, CPT1B | MEN1 1993/4885KMT2A 2403/4885MAPK1 4658/4885 |
| US-11674140-B2 | Compositions and methods for treating facioscapulohumeral dystrophy | MYOF, MTPN, CPT1B | MEN1 1993/4885KMT2A 2403/4885MAPK1 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.